Immunocore Holdings Plc (IMCR) Return on Equity ROE from the second quarter 2026 to second quarter 2025 and annually, average high and low, overall ranking from Jun 30 2026 to Jun 30 2025 - CSIMarket
CSIMarket Company Name, Ticker, Suppliers, else..
 


• ROA Quarterly
• ROI Quarterly
• ROE Quarterly
Immunocore Holdings Plc  (NASDAQ: IMCR)

Immunocore Holdings Plc's ROE per quarter

Return on Equity, Quarterly Results, Trends, Rankings, Statistics


What is ROE for Immunocore Holdings Plc in the second quarter 2026?
Immunocore Holdings Plc recorded a cumulative net loss of $-18 million during 12 months ending in the second quarter 2026, resulting in a negative return on equity (ROE) of -4.54%.

Within the Biotechnology & Pharmaceuticals industry 20 other companies had a higher return on equity. While return on equity, the total ranking has deteriorated compared to the first quarter 2026 from 1645 to 2609.

What is ROE?



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

Return On Equity (Jun 30 2026)
II. Quarter		 (Mar 31 2026)
I. Quarter		 (Dec 31 2025)
IV. Quarter		 (Sep 30 2025)
III. Quarter		 (Jun 30 2025)
II. Quarter
Y / Y Equity Change 8.06 % 4.01 % 5.63 % 4.96 % -
Y / Y Net Income Change - 158.23 % - - -
Net Income (TTM) in Millions -18 -28 -36 -29 -20
Return On Equity (TTM) -4.54 % -7.07 % -9.2 % -7.67 % -5.4 %
IMCR's Total Ranking # 2609 # 1645 # 2049 # 2269 # 2230
Equity (TTM) in Millions 420 394 381 397 388
Seq. Equity Change 6.64 % 3.32 % -3.92 % 2.08 % 2.64 %
Seq. Net Income Change - - - - -

Back to IMCR Management Effectiveness >> IMCR's 5 Years Annual ROE >> Compare IMCR ROE to its Competitors
Return On Equity Company Ranking
Within: No.
Industry # 21
Sector # 214
Overall # 2609

Return On Equity Statistics
High Average Low
-4.54 %
-7.68 %
-14.02 %
(Jun 30 2026)   (Dec 31 2024)



  News about Immunocore Holdings Plc Return on Equity ROE

Immunocore Advances Cancer Therapy Phase 1 Data on Brenetafusp Shows Promise in Ovarian Cancer Treatment

Immunocore Holdings Plc has marked a significant milestone in the realm of cancer therapies, as the company recently presented encouraging Phase 1 data on brenetafusp, a novel ImmTAC (Immune Mobilizing Monoclonal T cell receptors Against Cancer) bispecific targeting the cancer/testis antigen PRAME (Preferentially Expressed Antigen in Melanoma). This development comes at a crucial time for cancer patients and the broader oncology community, especially those grappling with ovarian cancer, a malignancy notorious for its late-stage diagnosis and limited treatment options.Brenetafusp operates by re-engineering the body s immune response, harnessing T-cells to target and destroy cancer cells expressing PRAME. The results from the Phase 1 trial indicate a promising safety profile alongside a preliminary indication of clinical activity within a patient cohort that has seen limited success with conventional therapies. The data, which highlights responses in some patients, brings hope to those previously considered to have few therapeutic avenues.



IMCR Annual Return On Equity (Dec 31 2025)
2025		 (Dec 31 2024)
2024		 (Dec 31 2023)
2023		 (Dec 31 2022)
2022		 (Dec 31 2021)
2021
Total Equity in Millions 381 361 369 339 234
Y / Y Equity Change 5.63 % -2.2 % 8.83 % 45.01 % 1092.39 %
Net Income in Millions -36 -51 -55 0 0
Y / Y Net Income Change - - - - -
Return On Equity -9.32 % -14.16 % -14.99 % 0 % 0 %

Back to IMCR Management Effectiveness >> IMCR's 5 Years Annual ROE >> Compare IMCR ROE to its Competitors




More Return On Equity Ratios
Biotechnology & Pharmaceuticals Industry Roe Trends and Statistics
Healthcare Sector Return On Equity Statistics
IMCR's' Return on Equity at Yahoo Finance
IMCR's Roe Ratio versus Biotechnology & Pharmaceuticals Industry, Healthcare Sector and overall Market
Highest Ranking Return On Equity
Lowest Ranking Return On Equity
Subscribers only: Roe for IMCR's Competitors
Subscribers only: Roe for Immunocore Holdings Plc's Suppliers
Subscribers only: Return On Equity for IMCR's Customers




Companies with similar Return On Equity at Jun 30 2026, within Healthcare Sector ROE

Date modified: 2026-09-26T07:42:46+00:00



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.